

[PUBLICATIONS](#) [BROWSE BY SUBJECT](#) [RESOURCES](#) [ABOUT US](#)

[Home](#) > [Pharmacology & Pharmaceutical Medicine](#) > [Pharmacology & Pharmaceutical Medicine](#) > [Phytotherapy Research](#) > [Vol 22 Issue 9](#) > [Abstract](#)



Research Article

## **Food supplementation with an olive (*Olea europaea* L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins**

Tania Perrinjaquet-Moccetti<sup>1,\*</sup>, Andreas Busjahn<sup>2</sup>, Caesar Schmidlin<sup>1</sup>, Annette Schmidt<sup>1</sup>, Barbara Bradl<sup>3</sup>, Cem Aydogan<sup>1</sup>

Article first published online: 27 AUG 2008

DOI: 10.1002/ptr.2455

Copyright © 2008 John Wiley & Sons, Ltd.

Issue



**Phytotherapy Research**

[Volume 22, Issue 9](#), pages 1239–1242, September 2008

Additional Information ([Show All](#))

[How to Cite](#) [Author Information](#) [Publication History](#) [Funding Information](#)

Abstract [References](#) [Cited By](#)

[Get PDF \(87K\)](#)

### **Keywords:**

*Olea europaea* L. leaf extract; EFLA<sup>®</sup>943; blood pressure; antihypertensive effect; LDL-cholesterol

### **Abstract**

Hypertension is a harmful disease factor that develops unnoticed over time. The treatment of hypertension is aimed at an early diagnosis followed by adequate lifestyle changes rather than pharmacological treatment. The olive leaf extract EFLA<sup>®</sup>943, having antihypertensive actions in rats, was tested as a food supplement in an open study including 40 borderline hypertensive monozygotic twins. Twins of each pair were assigned to different groups receiving 500 or 1000 mg/day EFLA<sup>®</sup>943 for 8 weeks, or advice on a favourable lifestyle. Body weight, heart rate, blood pressure, glucose and lipids were measured fortnightly. Blood pressure changed significantly within pairs, depending on the dose, with mean systolic differences of  $\leq 6$  mmHg (500 mg vs control) and  $\leq 13$  mmHg (1000 vs 500 mg), and diastolic differences of  $\leq 5$  mmHg. After 8 weeks, mean blood pressure remained unchanged from baseline in controls (systolic/diastolic:  $133 \pm 5/77 \pm 6$  vs  $135 \pm$

11/80 ± 7 mmHg) and the low-dose group (136 ± 7/77 ± 7 vs 133 ± 10/76 ± 7), but had significantly decreased for the high dose group (137 ± 10/80 ± 10 vs 126 ± 9/76 ± 6). Cholesterol levels decreased for all treatments with significant dose-dependent within-pair differences for LDL-cholesterol. None of the other parameters showed significant changes or consistent trends. Concluding, the study confirmed the antihypertensive and cholesterol-lowering action of EFLA<sup>®</sup>943 in humans. Copyright © 2008 John Wiley & Sons, Ltd. [Get PDF \(87K\)](#)

### More content like this

Find more content: [like this article](#)

Find more content written by: [Tania Perrinjaquet-Moccetti](#) [Andreas Busjahn](#) [Caesar Schmidlin](#) [Annette Schmidt](#) [Barbara Bradl](#) [Cem Aydogan](#) [All Authors](#)

### JOURNAL TOOLS

[Get New Content Alerts](#) [Get RSS feed](#) [Save to My Profile](#) [Get Sample Copy](#) [Recommend to Your Librarian](#)

### JOURNAL MENU

[Journal Home](#)

### FIND ISSUES

[Current Issue](#) [All Issues](#)

### FIND ARTICLES

[Early View](#)

### GET ACCESS

[Subscribe / Renew](#)

### FOR CONTRIBUTORS

[OnlineOpen](#) [Author Guidelines](#) [Submit an Article](#)

### ABOUT THIS JOURNAL

[Overview](#) [Editorial Board](#) [Permissions](#) [Advertise](#) [Contact](#)

### SPECIAL FEATURES

[Wiley Job Network](#)

### SEARCH

[Advanced >](#) [Saved Searches >](#)

### ARTICLE TOOLS

[Get PDF \(87K\)](#) [Save to My Profile](#) [E-mail Link to this Article](#) [Export Citation for this Article](#)  
[Get Citation Alerts](#) [Request Permissions](#)